» Articles » PMID: 16538527

Increased Prevalence of Prior Breast Cancer in Women with Newly Diagnosed Diabetes

Overview
Specialty Oncology
Date 2006 Mar 16
PMID 16538527
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: There is growing evidence of a link between type 2 diabetes and breast cancer, possibly through insulin resistance and/or hyperinsulinemia. Because insulin levels are at their highest prior to the development of diabetes, breast cancer risk may be even greater during the pre-diabetes period.

Research Design And Methods: In this cross-sectional study, women aged 55-79 years living in Ontario, Canada, with newly diagnosed diabetes from 1994 to 2002 were identified from a validated, population-based database (N = 82,390). Prior history of breast cancer in this group was recorded from 1964 until their diabetes diagnosis from a linkable cancer registry, and was compared to a similarly aged comparison group without diabetes (N = 411,950).

Results: Prior breast cancers were identified in 3.7% of women with diabetes and in 3.1% women without diabetes (odds ratio, OR 1.22, 95% confidence interval, CI 1.17-1.27, p < 0.0001). The mean time from breast cancer diagnosis to diabetes diagnosis was 7.9 years. The likelihood of a breast cancer history remained significantly higher in women with diabetes after adjustment for age, income and physician visits (OR 1.13, 95% CI 1.09-1.18, p < 0.0001).

Conclusions: These results suggest that breast cancer risk may be increased in the pre-diabetes phase and may have implications for screening and prevention strategies. Further studies are required to better characterize the processes that link insulin resistance, diabetes and breast cancer.

Citing Articles

Association between prediabetes and breast cancer: a comprehensive meta-analysis.

Keesari P, Jain A, Ganampet N, Subhasri G, Edusa S, Muslehuddin Z Breast Cancer Res Treat. 2023; 204(1):1-13.

PMID: 38060076 DOI: 10.1007/s10549-023-07181-x.


Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.

Thomas N, Scalzo R, Wellberg E Nat Rev Endocrinol. 2023; 20(1):16-26.

PMID: 37783846 PMC: 11487546. DOI: 10.1038/s41574-023-00899-0.


Age Specific Risks of Uterine Cancer in Type 2 Diabetes and Associated Comorbidities in Taiwan.

Liu H, Chen C, Lee C, Chen Y, Cheng W Cancers (Basel). 2022; 14(19).

PMID: 36230836 PMC: 9564306. DOI: 10.3390/cancers14194912.


Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth.

Cao M, Isaac R, Yan W, Ruan X, Jiang L, Wan Y Nat Cell Biol. 2022; 24(6):954-967.

PMID: 35637408 PMC: 9233030. DOI: 10.1038/s41556-022-00919-7.


Incident Type 2 Diabetes Risk of Selective Estrogen Receptor Modulators in Female Patients with Breast Cancer.

Choi Y, Bak K, Yeo Y, Choi Y, Shin S Pharmaceuticals (Basel). 2021; 14(9).

PMID: 34577625 PMC: 8472249. DOI: 10.3390/ph14090925.